{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:44:07Z","timestamp":1782920647411,"version":"3.54.5"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018592","name":"Celltrion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010780","name":"Celltrion Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jbspin.2026.106058","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:21:55Z","timestamp":1774398115000},"page":"106058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and pharmacological outcomes after switching from intravenous to subcutaneous infliximab in chronic inflammatory rheumatic diseases"],"prefix":"10.1016","volume":"93","author":[{"given":"Olivier","family":"Fogel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Bottois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Laure","family":"Tourneur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Dauchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"D\u2019Alessandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Gaud-Listrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Goulvestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Habhab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Souffir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Miceli-Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Molt\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Avouac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6149-0002","authenticated-orcid":false,"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2026.106058_bib0115","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2026.106058_bib0120","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2026.106058_bib0125","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/rheumatology\/keaa580","article-title":"Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I\/III trial","volume":"60","author":"Westhovens","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2026.106058_bib0130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13075-021-02487-x","article-title":"Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials","volume":"23","author":"Combe","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2026.106058_bib0135","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jbspin.2026.106058_bib0140","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","article-title":"Subcutaneous Infliximab (CT-P13 SC) as maintenance therapy for inflammatory bowel disease: two randomized phase 3 trials (LIBERTY)","volume":"167","author":"Hanauer","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jbspin.2026.106058_bib0145","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.clinthera.2014.05.062","article-title":"Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims","volume":"36","author":"Curtis","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.jbspin.2026.106058_bib0150","doi-asserted-by":"crossref","first-page":"1583401","DOI":"10.3389\/fmed.2025.1583401","article-title":"Switching from intravenous to subcutaneous infliximab in patients with immune mediated diseases in clinical remission","volume":"12","author":"Viazis","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jbspin.2026.106058_bib0155","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.cgh.2022.08.011","article-title":"Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: the REMSWITCH Study","volume":"21","author":"Buisson","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jbspin.2026.106058_bib0160","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/apt.17822","article-title":"Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: the REMSWITCH-LT study","volume":"59","author":"Buisson","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jbspin.2026.106058_bib0165","doi-asserted-by":"crossref","first-page":"e001105","DOI":"10.1136\/bmjgast-2023-001105","article-title":"Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)","volume":"10","author":"Carbery","year":"2023","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.jbspin.2026.106058_bib0170","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40744-018-0138-y","article-title":"Tocilizumab effectiveness after switching from intravenous to subcutaneous route in patients with rheumatoid arthritis: the RoSwitch study","volume":"6","author":"Darloy","year":"2019","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.jbspin.2026.106058_bib0175","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/acr.22598","article-title":"Sustainable efficacy of switching from intravenous to subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis","volume":"67","author":"Ogata","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2026.106058_bib0180","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.semarthrit.2017.10.002","article-title":"Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: the experience of Cochin University Hospital, Paris, France","volume":"47","author":"Avouac","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2026.106058_bib0185","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.semarthrit.2020.02.007","article-title":"Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice","volume":"50","author":"Lauret","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2026.106058_bib0190","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00228-020-02957-2","article-title":"Doctor's aptitude for switching from innovator etanercept to biosimilar etanercept in inflammatory rheumatic diseases: experience from a single French rheumatology tertiary care center","volume":"77","author":"Al Tabaa","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jbspin.2026.106058_bib0195","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s10067-017-3587-8","article-title":"Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration?. A questionnaire-based study","volume":"36","author":"Desplats","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2026.106058_bib0200","doi-asserted-by":"crossref","first-page":"e05205","DOI":"10.1002\/ccr3.5205","article-title":"Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID-19) pandemic: a case series","volume":"10","author":"Baraliakos","year":"2022","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.jbspin.2026.106058_bib0205","first-page":"549","article-title":"Safety and efficacy of transitioning inflammatory bowel disease patients from intravenous to subcutaneous infliximab: a single-center real-world experience","volume":"36","author":"Jeffrey","year":"2023","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.jbspin.2026.106058_bib0210","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/03007995.2025.2492638","article-title":"A real-world, observational, prospective cohort study evaluating the safety and effectiveness of CT-P13 in inflammatory bowel disease and rheumatoid arthritis: the MEGA-J study","volume":"41","author":"Ishida","year":"2025","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jbspin.2026.106058_bib0215","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/ecco-jcc\/jjac053","article-title":"Efficacy and safety of elective switching from intravenous to subcutaneous infliximab [CT-P13]: a multicentre cohort study","volume":"16","author":"Smith","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jbspin.2026.106058_bib0220","doi-asserted-by":"crossref","first-page":"e001047","DOI":"10.1136\/rmdopen-2019-001047","article-title":"Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial","volume":"6","author":"Ducourau","year":"2020","journal-title":"RMD Open"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X26000278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X26000278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:47:44Z","timestamp":1782917264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X26000278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1297319X26000278"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2026.106058","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and pharmacological outcomes after switching from intravenous to subcutaneous infliximab in chronic inflammatory rheumatic diseases","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2026.106058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Fran\u00e7aise de Rhumatologie.","name":"copyright","label":"Copyright"}],"article-number":"106058"}}